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tion that arises after major abdominal surgery. VTE poses risks of
negative outcomes and health care burden. The literature on the cost
of VTE in Japanese surgical patients, however, is scarce. Objective:
This study was conducted to investigate the economic consequences
of VTE in Japanese patients with major abdominal surgery, using a
hospital claims database. Methods: This is a retrospective, matched
cohort study. Patients who had a VTE event up to 90 days after their
ﬁrst major abdominal surgery and initiated warfarin or heparin
within 1 day of VTE diagnosis with continued treatment for more
than 4 weeks were matched with controls for surgery type, hospital,
and date of surgery  6 months in a 1:2 scheme. The primary
outcome was 90-day costs associated with major abdominal surgery.
The secondary outcomes were 6-month total costs, average length ofee front matter Copyright & 2015, International S
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.1016/j.vhri.2015.03.017
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ondence to: Bruce Crawford, IMS Health, Toranomoinitial inpatient stay, and cost of initial inpatient stay. Results: The
90-day cumulative incidence of VTE was 4.89%. The development of a
VTE event in patients undergoing major abdominal surgery resulted
in a 1.5-fold increase in the length of hospitalization and a 2.8-fold
increase in total costs 90 days after the surgery. Total costs further
increased to 3.4-fold at 6 months. Overall, costs incurred in patients
with VTE are on average much higher than in patients without VTE
throughout 6-month postsurgery. Conclusions: The preventive care
for VTE using more effective prophylactic treatment is recommended
to reduce the economic burden associated with major abdominal
surgery.
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Venous thromboembolism (VTE), deﬁned as either deep vein
thrombosis (DVT) or pulmonary embolism (PE), is a serious,
common complication that arises after major abdominal surgery.
It can occur in patients as a result of prolonged immobilization,
impairment of venous function, or impairment of endogenous
anticoagulant or ﬁbrinolytic systems [1]. Recurrent VTE and
postthrombotic syndrome are both serious sequelae of DVT,
and postthrombotic syndrome may further cause persistent
symptoms such as chronic edema, dermatitis, ambulatory
venous hypertension, and venous ulceration [1,2]. Postthrombotic
syndrome is characterized by swelling, pain, and discomfort that
are typically most pronounced at the end of the day and are
aggravated by standing and walking [3]. PE is a major cause ofsudden death after surgery and is manifested by clinical symp-
toms including dyspnea, chest pain, and syncope [4].
In Japan, the incidence of clinical PE after general surgery was
reported to be 0.33% [5]. The mortality rate of patients with PE
was 31%, and fatal PE was reported in 0.08% of the surgical
population [5]. In addition, evidence suggests that in some
patients, the risk of developing VTE may persist for several weeks
after a triggering event such as a major abdominal surgery [6].
Although the occurrence of VTE has been reported to be
relatively low in the Asian population, its incidence has increased
rapidly in the past decade in Japan to 0.02% of total births and
0.08% of total gynecological operations in Japan between 1991
and 2000 [7]. The number of PE cases in obstetrics and gynecology
was reported to have increased by 6.5-fold over the past 10 years.
One more recent study reported the incidence of postoperativeociety for Pharmacoeconomics and Outcomes Research (ISPOR).
yashi, Toru Shimazui, and Norimasa Seo received advisory board
n Towers Ofﬁce, 4-1-28 Toranomon, Minato-ku, Tokyo 105-0001,
V A L U E I N H E A L T H R E G I O N A L I S S U E S 6 C ( 2 0 1 5 ) 7 3 – 7 974VTE in patients without chemical thromborphylaxis to be 7.7% in
Japan [8]. The incidence of VTE was also observed in 24.3% of the
173 Japanese patients undergoing open major laparotomy [9],
which was slightly more but comparable to that of the Caucasian
patient population undergoing general or gynecologic surgery
(15%–19%) [9–11]. Furthermore, besides the increasingly similar
VTE incidence in Asian and Western populations, the literature
suggests that patients in both regions may share the same risk
factors and VTE disease pattern [12].
VTE brings serious risks of negative outcomes to patients after
major surgery [1]. Its recurrence and complications also pose an
enormous burden on health care resources for its management
[13]. The age-adjusted mortality rate of patients with PE has
increased rapidly in the last 50 years in Japan [14]. Risk factors for
developing postoperative VTE include age over 40 years, obesity,
and stage III/IV cancer [1,12,15], and patients with gynecological
cancer undergoing major abdominal surgery demonstrated a 14-
fold greater probability of developing PE than did patients with
benign disease (P o 0.001) [16]. In addition, pharmacologic
thromboprophylaxis including low-molecular-weight heparin
(LMWH) is associated with an increased incidence of postoper-
ative bleeding complications that can be life-threatening [16].
Warfarin and heparin are used as common prophylaxis treat-
ments to prevent VTE. According to the Japan guideline for
prophylaxis and treatment of VTE [17], standard treatment
includes unfractionated heparin followed by warfarin for at least
3 months for patients with reversible risk factors. Treatment can
also be administered for a longer time when there are no apparent
risk factors or when patients have cancer or recurrent VTE [17].
Although several studies have investigated the cost associ-
ated with VTE in Western countries, there is a paucity of
literature describing the true costs associated with VTE after
major abdominal surgery in Japan [18–21]. The present study
investigated the incidence and economic consequences of having
a VTE event after major abdominal surgery, using electronic
hospital medical records.Methods
Data Source
Data were obtained from the database developed by Medical Data
Vision, Inc., an electronic hospital claims database containing
hospital medical records from hospitals across Japan. The data-
base contains health insurance claims for about 1 million
patients since 2003 [22], providing a large number of patient
samples needed to evaluate the incidence of clinical VTE. Anon-
ymous information including patient background, disease, med-
ications, tests, surgeries, and diagnosis procedure combination
claims is included in this database [22]. Data were extracted on all
major abdominal surgeries in the time frame between January 1,
2003, and October 31, 2009, to ensure an adequate number of
events given the expected low incidence.
Study Subjects
A major abdominal surgery was deﬁned as a principal procedure
of gastrointestinal surgery, urological surgery, and male and
female genitourinary surgery and was identiﬁed using receipt
codes, which are standardized codes used by the Ministry of
Health, Labour and Welfare for electronic claims processing.
These codes were associated with 68 International Classiﬁcation of
Diseases, Ninth Revision, Clinical Modiﬁcation codes. Patients who
underwent the deﬁned major abdominal surgery comprised the
primary population for the analysis. Patients who were aged 18
years or older and had at least 3 months data before the indexsurgery and 3 to 6 months postsurgery follow-up available were
included in the analysis. Patients who underwent more than one
of these procedures during the same inpatient admission were
excluded.
VTE Cases
The Japanese guideline for prophylaxis and treatment of VTE
suggests that unfractionated heparin followed by warfarin may
be used for the treatment of VTE and/or prevention of VTE before
the surgery or immediately after the surgery, depending on the
risk of VTE [17]. Given that prophylactic treatment cannot be
prescribed without an associated diagnostic code, utilizing only
the administration of unfractionated heparin or warfarin would
result in an excessively high false-positive VTE rate. Therefore,
candidate VTE cases were grouped into PE (using receipt codes
equivalent to the International Classiﬁcation of Diseases, Tenth
Revision code I269) or DVT (International Classiﬁcation of Diseases,
Tenth Revision code equivalence: I801, I802, and I803). After being
identiﬁed by PE and DVT codes, patients were considered poten-
tial cases if they had a DVT or PE diagnosis code up to 90 days
after their ﬁrst major abdominal surgery. Patients were also
required to have no VTE diagnosis from 90 to 7 days before
surgery to reduce the risk of patients with prior VTE being
included. In addition, those patients who received anticoagulants
up to 1 week before surgery or immediately after surgery as
prophylaxis may not be true VTE candidates despite the diag-
nosis code. Thus, it is possible for the identiﬁed VTE code to be
from prior VTE, and it would not be considered as a potential
postoperative VTE case. Therefore, additional criteria that require
warfarin or heparin to be initiated within 1 day of VTE diagnosis
(to account for a delay in data entry) and patients to receive an
anticoagulant for more than 28 days were added. Those patients
who used an anticoagulant for 28 days or less were assumed to be
on prophylaxis treatment only and were thus excluded. In
addition to the criteria mentioned above, patients with an
inferior vena cava ﬁlter placement (receipt codes equivalent to
the International Classiﬁcation of Diseases, Ninth Revision, Clinical
Modiﬁcation code of 38.7) within 128 days of surgery were assumed
to have a PE. The very strict criteria of inclusion were intention-
ally used here to ensure that all included cases were credible VTE
cases and to avoid the risk of reporting false incidence or costs
resulting from false VTE cases.
Matched Controls
Identiﬁed cases were matched to control cases on a 1:2 matching
scheme. Cases were matched on the basis of same surgery type,
at the same hospital, and a date of surgery  6 months. Because
of anticipated limited sample sizes, age and sex were not
included in the matching process. These criteria were expected
to reduce the impact of treatment practice changes that may
inﬂuence the costs and resource utilization associated with
surgery and the treatment of complications, including VTE.
To make sure patients’ eligibility for the analysis, it was
ensured that the patients’ primary point of contact for clinical
care was the matched hospital. If the patient attended the
hospital only for a surgery and received treatment for postdi-
scharge VTE elsewhere, neither the comprehensive treatment
costs for the “episode of care” for the surgical intervention nor
the possible postdischarge occurrence of VTE was captured.
Therefore, all patients with at least one additional visit during
the 6-month period after surgery were included.
Pharmacoeconomic Analyses
The primary outcome measure was 90-day costs associated with
major abdominal surgery. Secondary outcomes included total 6-
Table 1 – Patients’ demographic information for VTE
cases and matched controls
Characteristic Cases
(n ¼ 16)
Matched
controls*
(n ¼ 31)
Sex
Male 4 (25.0) 8 (25.8)
Female 12 (75.0) 23 (74.2)
Age (y) at time of procedure
Mean  SD 66.1  15.45 61.2  17.32
Median 70.50 65.00
Min–Max 38.0–87.0 25.0–83.0
Age categorized (y)
o70 7 (43.8) 20 (64.5)
70–79 6 (37.5) 5 (16.1)
Z80 3 (18.8) 6 (19.4)
Surgical intervention
V A L U E I N H E A L T H R E G I O N A L I S S U E S 6 C ( 2 0 1 5 ) 7 3 – 7 9 75month costs after surgery, average length of initial hospital stay,
and cost of hospital stay. Costs were broken down into pharmacy,
laboratory, medical treatment, and room charges. The analysis
was conducted from a health care payer perspective.
Nonparametric bootstrapped mean difference in costs
between cases and controls were presented on the basis of 1000
draws. Given that cost data are usually skewed, costs were also
evaluated with either a γ-distributed generalized linear model
(GLM) with a log-link function or ordinary least squares on log-
transformed costs, using a smearing estimate to the retrans-
formed costs to evaluate between-group differences. The γ-
distributed functional form is particularly useful because it
avoids issues with the retransformation of skewed data. Potential
covariates that were not included in the matching but may affect
costs such as age or sex were included in the model as covariates
to obtain an adjusted analysis. Covariates were retained if they
were signiﬁcant at the 0.10 level. Costs were presented as
Japanese yen (JPY) and US dollar (US $). The exchange rate was
calculated as US $1 ¼ 102 JPY (Google Finance May 14, 2014) [23].Gastrointestinal
procedure
9 (56.3) 18 (58.1)
Urology procedure 3 (18.8) 6 (19.4)
Male genital procedure 0 (0.0) 0 (0.0)
Female genital
procedure
4 (25.0) 7 (22.6)
Note. Values represent n (%) except where indicated.
VTE, venous thromboembolism.
* Controls matched on major abdominal surgery date, surgery
type, and clinic.Results
Study Population
A total of 348 patients who underwent major abdominal surgery
were selected as potential VTE cases. Among the pool of potential
cases, a total of 17 patients were identiﬁed to be true VTE cases,
including 5 patients having had their ﬁrst DVT and/or PE
occurrence 0 to 7 days after surgery, 4 patients 8 to 14 days after
surgery, 3 patients 15 to 30 days after surgery, 3 patients 31 to 60
days after surgery, and 2 patients 61 to 90 days after surgery. The
incidence of VTE after major abdominal surgery in true VTE cases
is presented in Figure. 1. The 90-day VTE cumulative incidence
was 4.89% in patients undergoing major abdominal surgery, and
71% occurred in the ﬁrst 30 days after the surgery.
One patient who was a true case but did not have adequate
data for the 90-day follow-up period was not included in demo-
graphic and cost analyses. Sixteen patients with VTE had both 90-
day and 6-month follow-up data and were matched to 31
controls. One VTE case could not be matched to two controls
and was matched to one control instead. A total of 12 patients
were identiﬁed as DVT cases with 23 matched controls, and 7
patients were identiﬁed as PE cases with 14 matched controls.Fig. 1 – Time course of VTE incidence after major abdominal
surgery. VTE, venous thromboembolism.Three patients had both DVT and PE while 13 patients had either
DVT or PE only.
The mean age of patients with VTE (n ¼ 16) with both 90-day
and 6-month follow-up data was 66.1  15.45 years, ranging from
38 to 87 years. The mean age of matched controls (n ¼ 31) was
61.2  17.32 years, ranging from 25 to 83 years. The majority were
female in both the VTE group (75.0%) and the control group
(74.2%), with more than half undergoing a gastrointestinal pro-
cedure. Demographic information is presented in Table 1.90-Day Evaluation
The average 90-day surgery-related costs were 2,106,047 
1,729,493 JPY ($20,648  $19,956) for patients with VTE and
747,703  569,943 JPY ($7,330  $5,588) for matched controls,
with a difference of 1,358,344 JPY ($13,317) (bootstrapped 95%
conﬁdence interval [95% CI] 598,232.64–2,268,952.25 JPY [$5,865–
$22,245]). When tested with the γ-distributed log-link GLM
adjusted for age and sex, costs for patients with VTE were
signiﬁcantly higher than for control patients (P o 0.0001). For
patients with DVT, the 90-day surgery-related costs were on
average 1,725,892  1,255,512 JPY ($16,921  $12,309) for the
patients and 719,669  552,332 JPY ($7,055  $5,415) for the
controls, with a difference of 1,006,223 JPY ($9,865) (bootstrapped
95% CI 394,549.24–1,785,004.98 JPY [$3,868–$17,500]; P ¼ 0.0004).
The 90-day surgery-related costs were on average 2,440,599 
2,129,532 JPY ($23,927  $20,878) for patients with PE and 886,953
 758,652 JPY ($8,696  $7,438) for controls, with a difference of
1,553,647 JPY ($15,231) (bootstrapped 95% CI 541,895.81–
3,308,983.22 JPY [$5,313–$32,441]; P ¼ 0.0044). Notably, room cost
data were missing for 1 VTE case and 14 controls matched to VTE
cases, 1 DVT case and 10 controls matched to DVT cases, and 1 PE
case and 8 controls matched to PE cases (Table 2).
The 90-day total costs after surgery are presented in Figure. 2.
Costs for patients with VTE were higher than those for controls in
each category. Because it requires additional health care resources
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each category for patients with VTE (Table 2). Differences between
the VTE group and the control group for pharmacy, laboratory,
medical, and room costs were 263,192 JPY ($2,580), 97,081 JPY
($952), 192,207 JPY ($1,884), and 665,763 JPY ($6,527), respectively. In
the DVT and PE patient groups, costs for each category were
greater than those of the controls. It is likely that the difference in
the length of the initial hospital stay affected the greater difference
in room costs.
The average length of initial hospital stay was not signiﬁ-
cantly different between patients with VTE (40.9  33.31 days)
and controls (26.9  40.34 days; P ¼ 0.0683). Similar results were
found for patients with DVT and patients with PE compared with
their respective matched controls.6-Month Evaluation
All patients with at least 90-day follow-up data also had adequate
6-month follow-up data available. The 6-month total costs after
surgery were on average 2,705,929  2,015,851 JPY ($26,529 
$19,763) for patients with VTE and 789,297  577,249 JPY ($7,738 
$5,659) for matched controls. The mean difference was 1,916,632
JPY ($18,791) (bootstrapped 95% CI 1,050,081.27–3,001,754.58 JPY
[$10,295–$29,429]). The average total 6-month cost in patients
with VTE was signiﬁcantly greater than in control patients, when
tested with the γ-distributed log-link GLM adjusted for age and
sex (P o 0.0001).
The 6-month costs associated with surgery were on average
2,184,604  1,500,493 JPY ($21,418  $14,711) for patients with
DVT and 759,980  557,664 JPY ($7,451  $5,663) for controls. The
difference was 1,424,624 JPY ($13,967) (bootstrapped 95% CI
565,595.61–2,279,833.24 JPY [5,545–$22,351]; P o 0.0001). For
patients with PE, the 6-month cost associated with surgery was
on average 3,254,957  2,424,283 JPY ($31,911  $23,767) for the
patients and 936,003  760,538 JPY ($9,177  $7,456) for controls.
The difference was 2,318,954 JPY ($22,735) (bootstrapped 95% CI
1,011,867.35–4,261,785.06 JPY [$9,920–$41,782]; P ¼ 0.0003).
The composition of costs in the 6-month period after surgery
is presented in Table 2. For each category, costs were greater in
patients with VTE than in matched controls. Differences between
the VTE group and the control group for pharmacy, laboratory,
medical, and room costs were 333,369 JPY ($3,268), 143,439 JPY
($1,406), 254,107 JPY ($2,491), and 984,879 JPY ($9,656), respec-
tively. Costs for each category were greater in the DVT and PE
patient groups than in the control groups (Table 2).Initial Hospitalization
The total costs associated with the initial hospital stay were on
average 1,873,159  1,996,173,664 JPY ($18,364  $19,570) for
patients with VTE and 864,386  799,242 JPY ($8,474  $7,836)
for matched controls, with a mean difference of 1,008,773 JPY
($9,890) (bootstrapped 95% CI 134,986.23–2,159,696.54 JPY [$1,323–
$21,173]). Costs were signiﬁcantly higher for patients with VTE in
the γ-distributed log-link GLM test adjusted for age and sex (P ¼
0.0158). The total costs associated with the initial hospital stay
were 1,491,176  1,331,823 JPY ($14,619  $13,057) for patients
with DVT and 830,542  768,936 JPY ($8,143  $7,539) for controls,
with a mean difference of 660,634 JPY ($6,477) (bootstrapped 95%
CI 48,520.91 to 1,479,818.51 JPY [$476 to $14,508]). The total
costs associated with the initial hospital stay were 2,352,533 
2,523,217 JPY ($23,064  $24,737) for patients with PE and 992,060
 932,513 JPY ($9,726  $9,142) for controls, with a mean differ-
ence of 1,360,473 JPY ($13,338) (bootstrapped 95% CI 157,807.55–
3,625,241.40 JPY [$1,547–$35,542]). Costs for the DVT and PE
patient groups were not signiﬁcantly higher than those for
400,668
(593,816)
193,439
(143,185)
485,484
(346,726)
981,936
(674,714)
137,476 
(261,030) 96,358
(114,663)
293,277
(143,241)
316,173
(248,813)
0
200,000
400,000
600,000
800,000
1,000,000
1,200,000
Pharmacy Laboratory Medical Room 
M
ea
n 
co
st
s 
(S
D
) i
n 
Ja
pa
ne
se
 Y
en
 (J
PY
)
Cost categories
VTE Cases VTE Controls
Fig. 2 – Mean 90-day costs (JPY) by category for patients with VTE and matched control patients. VTE, venous
thromboembolism.
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and sex (P ¼ 0.0936 and 0.0601, respectively).Cost Time Course
The overall costs associated with major abdominal surgery from
30 days before the surgery date through 6 months after surgery
are presented in Figure. 3. There was an immediate and large
separation of costs between patients with VTE and matched
controls. The absolute costs for the 30-day period before the
surgery were approximately the same for both groups. The mean
difference in costs, however, markedly increased to 677,165 JPY
($6,639) 30 days after the procedure when the greatest costs were
incurred for both groups. Costs for patients with VTE remained
generally much higher than those for controls throughout the 6
months after surgery, with costs for controls quickly decreasingFig. 3 – Cumulative mean costs (JPY) from 30 days before major a
with VTE and matched control patients. VTE, venous thromboe31 to 60 days after surgery and the average amount starting to
plateau past 61 days after surgery below 30,000 JPY ($294). The
cumulative costs of VTE peaked at 6 months, resulting in the
greatest difference in mean costs of 1,866,109 JPY ($18,295)
between the VTE patient and control groups. The cumulative
costs incurred demonstrated the large economic impact of VTE
on the health care system.Discussion
To our knowledge, this study is the ﬁrst study describing the true
costs associated with VTE after major abdominal surgery in
Japan. The 90-day cost was found to be 2,106,047 JPY ($20,648).
There was a 1.5-fold increase in the length of hospitalization and
a 2.8-fold increase in total costs over 90 days in patients with VTEbdominal surgery through 6 months after surgery in patients
mbolism.
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the other VTE cost study [24]. The study investigating the cost of
VTE after major orthopedic surgery reported a mean cost of
1,992,713 JPY for the VTE group, compared with 1,128,560 JPY in
the non-VTE matched control group [24]. They also found that
patients with VTE had a 1.5-fold increase in the length of
hospitalizations [24]. An annual VTE cost of around $10,000 to
$33,000 was reported in the United States [18–20]. A more recent
matched-cohort study indicated that the annual cost of patients
with VTE was signiﬁcantly higher than that of patients without
VTE ($33,531 vs. $15,914). Similarly, another study in Italy
reported that the total median cost for VTE was approximately
4 times higher than for the non-VTE group (€1348.68 vs. €373.03)
[21]. Although the difference in health care systems and medical
practices as well as different methods and criteria used in the
previous literature make the results not directly comparable, our
results are consistent with previous ﬁndings in that VTE brought
signiﬁcant economic burden to the health care system.
The cumulative incidence of 4.89% in this study is similar to
but slightly lower than what has been reported in the literature
for patients with clinical VTE undergoing major abdominal
surgery with pharmacological prophylaxis [8,25,26]. In a recent
study in the Japanese population, the incidence of VTE in
patients without chemical thromboprophylaxis was reported to
be 7.7% [8]. In a meta-analysis of three randomized trials, Bottaro
et al. [25] reported an incidence of 5.93% for patients on extended
LMWH prophylaxis. They [25] also found that the incidence of
VTE increased to 6.2% over 3 months after major abdominal
surgery. In another meta-analysis of four randomized trials, the
incidence of overall VTE after major abdominal or pelvic surgery
was reported to be 14.3% in patients receiving placebo or no
treatment and 6.1% in patients receiving out-of-hospital LMWH
[26]. A possible reason of the slightly lower incidence compared
with that in the literature is that patients may have been
receiving mechanical prophylaxis in the present study. The
routine preventive care for VTE in Japan is mechanical prophy-
laxis such as elastic stocking or intermittent pneumatic com-
pression. The cost of this mechanical prophylaxis was included
in this study. Therefore, it is very important to investigate
whether the additional pharmacological prophylaxis is effective
or not, not only clinically but also cost-efﬁciently. In other words,
it is important to determine whether the cost for pharmacological
prophylaxis in all surgical patients exceeds the cost to be spent
for the treatment of VTE, that is, the greatest difference between
patients with VTE and control patients. In a similar clinical
setting to this study, a short-term (7–14 days) perioperative
administration of enoxaparin, one of available anticoagulants
for thromboprophylaxis in Japan, was shown to drastically
reduce the incidence of VTE from 19.4% (control group) to 1.2%
(enoxaparin group) [27]. In the current setting, the maximum
total cost per patient that can be spent for VTE prophylaxis with
enoxaparin is calculated as 85,608 JPY ($839.29), calculated as the
proportion of risk reduction attributed to thromboprophylaxis:
[(19.4% –1.2%)/19.4%] times the cost difference for VTE (1,866,109
JPY) and VTE rate (4.89%). This is equivalent to the cost of
enoxaparin (2,072 JPY [$20.31]/d) administration for 41 days.
Likewise, it is equivalent to the 38-days administration cost of
another available anticoagulant, fondaparinux (2,207 JPY [$21.64]/
d). Thus, the pharmacological thromboprophylaxis in addition to
mechanical prophylaxis would be considered cost-effective in
major abdominal surgery in Japan.
This study also has several limitations. First, very restrictive
criteria were used for the identiﬁcation of VTE in this study, which
ensured that the selected cases were credible true cases and
therefore the costs are highly reﬂective of the true costs. Still, a
few VTE cases were possibly classiﬁed as non-VTE cases because
of the restrictive criteria, but this would have driven the costdifferences toward no signiﬁcant difference. The associated
cumulative incidence can also be underestimated because of
these restrictive criteria and would be considered a lower bound.
Second, there is limitation resulting from the use of hospital
electronic records in Japan. Compared with the Western coun-
tries, the current health care medical records databases in Japan
are still largely underdeveloped. Despite the accelerated develop-
ment of these databases, their current breadth remains a limi-
tation. Because the database used in this study captures
electronic records for 13 hospitals throughout Japan, the number
of surgeries was quite small. Generalization to the rest of Japan
can be problematic because of the limited number of hospitals.
Nevertheless, both diagnosis procedure combination and non–
diagnosis procedure combination hospitals are included in the
database, which can reﬂect the real-world composition of health
care situation in Japan. For a more comprehensive study through-
out Japan, data from more rural hospitals and hospitals in the
southern islands would be required. Given the limitations of data
availability, the present study has taken a huge step forward in
analyzing the economic burden brought by postoperative VTE.
There may have been some potential bias due to the lack of
matching on age and sex; however, there were surgeries speciﬁc
to men and women, such as hysterectomy or uterine tumor
surgery, which would account for lack of sex matching. Matching
on age would have required a large range, which may not have
been useful. The speciﬁcity of the surgery matching may have
accounted in part for similar ages. Both age and sex were
included as covariates in the γ-distributed log-link GLM analysis,
which should help control for some of their inﬂuence.
Last, our patients with VTE were at a higher risk of developing
a VTE caused by comorbidities. However, we were not able to
develop a reliable Charlson comorbidity index because of the use
of hospital-based claims in the present study. A comorbidity
index could not be developed unless consistent recording of
comorbid conditions could be extracted, meaning that the
patients would need to use the same hospital for their primary
care. Instead, we managed to control several factors. Using the
matching scheme of the hospital, the surgery type, and the date
of surgery (within 6 months), we controlled for changes in
practice patterns between hospitals and were thus able to
maintain the same balance of surgery type in the VTE cases
and control groups. We also controlled for age and sex in our
multivariate analysis. Hence, although it is possible that comor-
bidities might affect our ﬁndings, our adjusting other factors
hope to limit it to the minimal extent.
In conclusion, the development of VTE after major abdominal
surgery has brought an enormous economic burden on the health
care system. Because VTE is a preventable disease, pharmaco-
logical prophylaxis should be recommended as a common prac-
tice to reduce both the clinical and economic burden in Japan
[25,26]. Prevention through more effective prophylactic treatment
in Japanese patients will help to reduce the signiﬁcant cost
caused by postoperative VTE.
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